UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’

Start-Up Raises $17.5m In Series A

 
• By Andrew McConaghie

Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.

London_Francis_Crick
Ervaxx has been spun out of technology developed at the Francis Crick Institute

More from R&D

More from Scrip